{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:15:22Z","timestamp":1793826922763,"version":"4.6.1"},"reference-count":56,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In diffuse large B-cell lymphoma (DLBCL), tumor-infiltrating T lymphocytes (TILs) are involved in therapeutic responses. However, tumor-specific TILs can be dysfunctional, with impaired effector functions. Various mechanisms are involved in this exhaustion, and the increased expression of programmed cell death receptor 1 (PD1) and TIM3 on dysfunctional cells suggests their involvement. However, conflicting data have been published regarding their expression or coexpression in DLBCL. We evaluated the presence and phenotype of CD4+ and CD8+ TILs in freshly collected tumor tissues in DLBCL and compared the results with those in follicular lymphoma, classical Hodgkin lymphoma, and nonmalignant reactive lymphadenopathy. We found that TILs expressing both PD1 and TIM3 were expanded in DLBCL, particularly in the activated B cell\u2013like subgroup. Isolated PD1+TIM3+ TILs exhibited a transcriptomic signature related to T-cell exhaustion associated with a reduction in cytokine production, both compromising the antitumor immune response. However, these cells expressed high levels of cytotoxic molecules. In line with this, stimulated PD1+TIM3+ TILs from DLBCL patients exhibited reduced proliferation and impaired secretion of interferon-\u03b3, but these functions were restored by the blockade of PD1 or TIM3. In summary, the PD1+TIM3+ TIL population is expanded and exhausted in DLBCL but can be reinvigorated with appropriate therapies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003080","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T15:46:19Z","timestamp":1617205579000},"page":"1816-1829","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":73,"title":["Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9741-0668","authenticated-orcid":false,"given":"Mika\u00ebl","family":"Roussel","sequence":"first","affiliation":[{"name":"Microenvironment, Cell Differentiation, Immunology, and Cancer\u2013UMR_S1236, Universit\u00e9 de Rennes, \u00c9tablissement Fran\u00e7ais du Sang de Bretagne, INSERM, Rennes, France;"},{"name":"Laboratoire d\u2019H\u00e9matologie, Centre Hospitalier Universitaire, Rennes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieu-Suong","family":"Le","sequence":"additional","affiliation":[{"name":"INSERM UMR 1068, Centre National de la Recherche Scientifique UMR 7258, Universit\u00e9 Aix Marseille and Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Granier","sequence":"additional","affiliation":[{"name":"Service Immunologie Biologique, H\u00f4pital Europ\u00e9en Georges Pompidou, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France;"},{"name":"INSERM U970, Paris Cardiovascular Research Center (PARCC), Paris, France;"},{"name":"Equipe Labellis\u00e9e Ligue Contre le Cancer, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Llamas Gutierrez","sequence":"additional","affiliation":[{"name":"Service d\u2019Anatomie Pathologique, Centre Hospitalier Universitaire, Rennes, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Foucher","sequence":"additional","affiliation":[{"name":"INSERM UMR 1068, Centre National de la Recherche Scientifique UMR 7258, Universit\u00e9 Aix Marseille and Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Le Gallou","sequence":"additional","affiliation":[{"name":"Microenvironment, Cell Differentiation, Immunology, and Cancer\u2013UMR_S1236, Universit\u00e9 de Rennes, \u00c9tablissement Fran\u00e7ais du Sang de Bretagne, INSERM, Rennes, France;"},{"name":"Laboratoire d\u2019H\u00e9matologie, Centre Hospitalier Universitaire, Rennes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Pangault","sequence":"additional","affiliation":[{"name":"Microenvironment, Cell Differentiation, Immunology, and Cancer\u2013UMR_S1236, Universit\u00e9 de Rennes, \u00c9tablissement Fran\u00e7ais du Sang de Bretagne, INSERM, Rennes, France;"},{"name":"Laboratoire d\u2019H\u00e9matologie, Centre Hospitalier Universitaire, Rennes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Xerri","sequence":"additional","affiliation":[{"name":"INSERM UMR 1068, Centre National de la Recherche Scientifique UMR 7258, Universit\u00e9 Aix Marseille and Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Launay","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Centre Hospitalier, Centre Hospitalier Universitaire, Saint Brieuc, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lamy","sequence":"additional","affiliation":[{"name":"Microenvironment, Cell Differentiation, Immunology, and Cancer\u2013UMR_S1236, Universit\u00e9 de Rennes, \u00c9tablissement Fran\u00e7ais du Sang de Bretagne, INSERM, Rennes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tartour","sequence":"additional","affiliation":[{"name":"Service Immunologie Biologique, H\u00f4pital Europ\u00e9en Georges Pompidou, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France;"},{"name":"INSERM U970, Paris Cardiovascular Research Center (PARCC), Paris, France;"},{"name":"Equipe Labellis\u00e9e Ligue Contre le Cancer, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1299-4113","authenticated-orcid":false,"given":"Daniel","family":"Olive","sequence":"additional","affiliation":[{"name":"INSERM UMR 1068, Centre National de la Recherche Scientifique UMR 7258, Universit\u00e9 Aix Marseille and Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6437-4189","authenticated-orcid":false,"given":"Thierry","family":"Fest","sequence":"additional","affiliation":[{"name":"Microenvironment, Cell Differentiation, Immunology, and Cancer\u2013UMR_S1236, Universit\u00e9 de Rennes, \u00c9tablissement Fran\u00e7ais du Sang de Bretagne, INSERM, Rennes, France;"},{"name":"Laboratoire d\u2019H\u00e9matologie, Centre Hospitalier Universitaire, Rennes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"issue":"19","key":"2021033115461248700_B1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"22","key":"2021033115461248700_B2","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","article-title":"Clinical impact of the cell-of-origin classification and the MYC\/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group","volume":"35","author":"Staiger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"2021033115461248700_B3","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021033115461248700_B4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"issue":"7749","key":"2021033115461248700_B5","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"issue":"12","key":"2021033115461248700_B6","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1084\/jem.188.12.2205","article-title":"Viral immune evasion due to persistence of activated T cells without effector function","volume":"188","author":"Zajac","year":"1998","journal-title":"J Exp Med"},{"issue":"8","key":"2021033115461248700_B7","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/JVI.77.8.4911-4927.2003","article-title":"Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment","volume":"77","author":"Wherry","year":"2003","journal-title":"J Virol"},{"issue":"8","key":"2021033115461248700_B8","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"2021033115461248700_B9","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"6332","key":"2021033115461248700_B10","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"issue":"3","key":"2021033115461248700_B11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10549-013-2581-3","article-title":"The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer","volume":"139","author":"Muenst","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2021033115461248700_B12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","article-title":"PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer","volume":"73","author":"Badoual","year":"2013","journal-title":"Cancer Res"},{"issue":"6","key":"2021033115461248700_B13","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-06-2599","article-title":"PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma","volume":"13","author":"Thompson","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2021033115461248700_B14","doi-asserted-by":"crossref","first-page":"e76008","DOI":"10.1371\/journal.pone.0076008","article-title":"Persistent changes in circulating and intestinal \u03b3\u03b4 T cell subsets, invariant natural killer T cells and mucosal-associated invariant T cells in children and adults with coeliac disease","volume":"8","author":"Dunne","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"2021033115461248700_B15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-014-2988-5","article-title":"Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer","volume":"146","author":"Muenst","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"2021033115461248700_B16","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021033115461248700_B17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.biopha.2015.08.037","article-title":"Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma","volume":"75","author":"Zhang","year":"2015","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"2021033115461248700_B18","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/cam4.874","article-title":"PD-1 expression on the surface of peripheral blood CD4+ T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma","volume":"5","author":"Zhang","year":"2016","journal-title":"Cancer Med"},{"issue":"22","key":"2021033115461248700_B19","doi-asserted-by":"crossref","first-page":"33350","DOI":"10.18632\/oncotarget.9061","article-title":"Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1\/PD-L1 axis activating intracellular AKT\/mTOR pathway in tumor cells","volume":"7","author":"Dong","year":"2016","journal-title":"Oncotarget"},{"issue":"15","key":"2021033115461248700_B20","doi-asserted-by":"crossref","first-page":"e6398","DOI":"10.1097\/MD.0000000000006398","article-title":"The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma","volume":"96","author":"Fang","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"19","key":"2021033115461248700_B21","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2021033115461248700_B22","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial","volume":"28","author":"Rossille","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"2021033115461248700_B23","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1038\/bcj.2015.1","article-title":"PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival","volume":"5","author":"Yang","year":"2015","journal-title":"Blood Cancer J"},{"issue":"1","key":"2021033115461248700_B24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol Rev"},{"issue":"10","key":"2021033115461248700_B25","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"issue":"10","key":"2021033115461248700_B26","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"issue":"4","key":"2021033115461248700_B27","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/hep.25777","article-title":"Tim-3\/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma","volume":"56","author":"Li","year":"2012","journal-title":"Hepatology"},{"issue":"2","key":"2021033115461248700_B28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/archdischild-2014-307212","article-title":"Recent advances in paediatric respiratory medicine","volume":"101","author":"Turnbull","year":"2016","journal-title":"Arch Dis Child"},{"issue":"5","key":"2021033115461248700_B29","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1158\/0008-5472.CAN-16-0274","article-title":"Tim-3 expression on tumor-infiltrating PD-1+CD8+ T cells correlates with poor clinical outcome in renal cell carcinoma","volume":"77","author":"Granier","year":"2017","journal-title":"Cancer Res"},{"issue":"15","key":"2021033115461248700_B30","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1158\/1078-0432.CCR-18-4175","article-title":"TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer","volume":"25","author":"Fucikova","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2021033115461248700_B31","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T cell IFN-\u03b3-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res"},{"issue":"16","key":"2021033115461248700_B32","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1158\/1078-0432.CCR-13-1432","article-title":"\u201cLicense to kill\u201d reflects joint action of CD4 and CD8 T cells","volume":"19","author":"Melief","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2021033115461248700_B33","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2021033115461248700_B34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2021033115461248700_B35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jmoldx.2015.01.007","article-title":"Accurate classification of germinal center B-cell-like\/activated B-cell-like diffuse large B-cell lymphoma using a simple and rapid reverse transcriptase-multiplex ligation-dependent probe amplification assay: a CALYM study","volume":"17","author":"Mareschal","year":"2015","journal-title":"J Mol Diagn"},{"issue":"1","key":"2021033115461248700_B36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40880-017-0262-z","article-title":"Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study","volume":"36","author":"Hu","year":"2017","journal-title":"Chin J Cancer"},{"issue":"37","key":"2021033115461248700_B37","doi-asserted-by":"crossref","first-page":"59976","DOI":"10.18632\/oncotarget.11045","article-title":"PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications","volume":"7","author":"Xing","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"2021033115461248700_B38","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy [published correction appears in J Clin Oncol. 2019;37(12):1035]","volume":"37","author":"Sha","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"2021033115461248700_B39","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/his.12882","article-title":"Clinicopathological analysis of programmed cell death-1 and programmed cell death-ligand 1 expression in the tumor microenvironments of diffuse large B-cell lymphomas","volume":"68","author":"Kwon","year":"2016","journal-title":"Histopathology"},{"issue":"1","key":"2021033115461248700_B40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2021033115461248700_B41","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2018889931","article-title":"PD-1\/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B cell diffuse large B-cell lymphomas","volume":"133","author":"Pascual","year":"2019","journal-title":"Blood"},{"issue":"7620","key":"2021033115461248700_B42","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nature19317","article-title":"Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection [published correction appears in Nature. 2016;540(7633):470]","volume":"537","author":"He","year":"2016","journal-title":"Nature"},{"key":"2021033115461248700_B43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-319-67577-0_2","article-title":"Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment","volume":"1036","author":"Gajewski","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"7528","key":"2021033115461248700_B44","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"8","key":"2021033115461248700_B45","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"issue":"3","key":"2021033115461248700_B46","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade [published correction appears in Nat Immunol. 2019;20(11):1556]","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"issue":"7620","key":"2021033115461248700_B47","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"issue":"7684","key":"2021033115461248700_B48","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature24993","article-title":"Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours [published correction appears in Nature. 2018;554(7692):392]","volume":"552","author":"Milner","year":"2017","journal-title":"Nature"},{"issue":"6111","key":"2021033115461248700_B49","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.1229620","article-title":"Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection","volume":"338","author":"Paley","year":"2012","journal-title":"Science"},{"issue":"6","key":"2021033115461248700_B50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"2021033115461248700_B51","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of \u03b22-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"issue":"6","key":"2021033115461248700_B52","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1182\/blood-2011-07-363820","article-title":"Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma","volume":"119","author":"Wilkinson","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2021033115461248700_B53","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/ijms21010068","article-title":"Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL","volume":"21","author":"Mhibik","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2021033115461248700_B54","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.3390\/ijms19124118","article-title":"Oligoclonal T cells transiently expand and express Tim-3 and PD-1 following anti-CD19 CAR T cell therapy: a case report","volume":"19","author":"Funk","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2021033115461248700_B55","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2021033115461248700_B56","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","article-title":"PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways","volume":"51","author":"Zhao","year":"2019","journal-title":"Immunity"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/7\/1816\/1804105\/advancesadv2020003080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/7\/1816\/1804105\/advancesadv2020003080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T15:47:07Z","timestamp":1617205627000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/7\/1816\/475596\/Functional-characterization-of-PD1-TIM3-tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,4,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003080","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]}}}